Trials / Completed
CompletedNCT06475846
A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults
A Evaluate HRS5580 for Injection for Prevention of Postoperative Nausea and Vomiting Efficacy and Safety of Ⅱ Period, Randomized, Multicenter, Dose of Exploration, Positive Control, Placebo-controlled, Double-blind, Double Simulation Trials
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 235 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS5580 | HRS5580; low dose |
| DRUG | HRS5580 | HRS5580; middle dose |
| DRUG | HRS5580 | HRS5580; middle dose |
| DRUG | Ondansetron | Ondansetron |
| DRUG | blank preparation | blank preparation. |
Timeline
- Start date
- 2024-06-25
- Primary completion
- 2024-10-29
- Completion
- 2024-10-29
- First posted
- 2024-06-26
- Last updated
- 2025-01-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06475846. Inclusion in this directory is not an endorsement.